Compressed orally disintegrating tablets: excipients evolution and formulation strategies

被引:59
|
作者
Al-khattawi, Ali [1 ]
Mohammed, Afzal R. [1 ]
机构
[1] Aston Univ, Aston Pharm Sch, Birmingham B4 7ET, W Midlands, England
关键词
compression; co-processing; mannitol; microcrystalline cellulose; orally disintegrating tablet; particle engineering; swallowing difficulty; MICROCRYSTALLINE CELLULOSE; DOSAGE FORM; MANNITOL; TRANSITION; STARCH; CROSPOVIDONE; PERFORMANCE; MEDICATION; DYSPHAGIA; MIXTURES;
D O I
10.1517/17425247.2013.769955
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Orally disintegrating tablets (ODTs) have emerged as one of the novel solid oral dosage forms with a potential to deliver a wide range of drug candidates to both paediatric and geriatric patient populations. Of the plethora of available technologies, compression of excipients offers a cost-effective and translatable methodology for the manufacture of ODTs. Areas covered: The review is a modest endeavour from the authors to assemble literature published over the last couple of decades on formulation development of compressed ODT. It describes the main ODT excipients used since the introduction of this dosage form in the 1990s and explores the switch from cellulose-based excipients towards sugar/polyols. Furthermore, it unfolds the key properties of ODT fillers, binders and disintegrants with an emphasis on their advantages and drawbacks. The review also provides a critical assessment of the various strategies employed for performance enhancement of compressed ODT with a focus on the underlying mechanisms for fast disintegration and acceptable mechanical strength. Expert opinion: Recent increase in the total number of compression-based technologies for ODT development promises to reduce the manufacturing cost of this dosage form in the future. However, some of the developed methods may affect the stability of tablets due to susceptibility to moisture, collapse of pores or the generation of less stable polymorphs which require rigorous testing prior to commercialization.
引用
收藏
页码:651 / 663
页数:13
相关论文
共 50 条
  • [31] Efficacy, Safety, and Palatability of RACTAB (R) Formulation Amlodipine Orally Disintegrating Tablets
    Fukui-Soubou, Mari
    Terashima, Hirotaka
    Kawashima, Kiyoshi
    Utsunomiya, Osamu
    Terada, Taichiroh
    [J]. DRUGS IN R&D, 2011, 11 (04) : 327 - 336
  • [32] Spray dried excipient base: A novel technique for the formulation of orally disintegrating tablets
    Mishra, DN
    Bindal, M
    Singh, SK
    Kumar, SGV
    [J]. CHEMICAL & PHARMACEUTICAL BULLETIN, 2006, 54 (01) : 99 - 102
  • [33] Formulation and In Vivo Evaluation of Ondansetron Orally Disintegrating Tablets Using Different Superdisintegrants
    Sheshala, Ravi
    Khan, Nurzalina
    Chitneni, Mallikarjun
    Darwis, Yusrida
    [J]. ARCHIVES OF PHARMACAL RESEARCH, 2011, 34 (11) : 1945 - 1956
  • [34] Formulation and in vivo evaluation of ondansetron orally disintegrating tablets using different superdisintegrants
    Ravi Sheshala
    Nurzalina Khan
    Mallikarjun Chitneni
    Yusrida Darwis
    [J]. Archives of Pharmacal Research, 2011, 34 : 1945 - 1956
  • [36] Comparison of superdisintegrants in orally disintegrating tablets
    Zhang, Yeli
    Wrzesinski, Amy
    Moses, Marley
    Bertrand, Holly
    [J]. Pharmaceutical Technology, 2010, 34 (07) : 54 - 61
  • [37] On the BCS biowaivers of orally disintegrating tablets
    Garcia-Arieta, Alfredo
    Gordon, John
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 66 : 107 - 108
  • [38] Dissolution testing of orally disintegrating tablets
    Kraemer, Johannes
    Gajendran, Jayachandar
    Guillot, Alexis
    Schichtel, Julian
    Tuereli, Akif
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2012, 64 (07) : 911 - 918
  • [39] PREPARATION OF FAMOTIDINE ORALLY DISINTEGRATING TABLETS
    Olmez, Senem Sevtap
    Vural, Imran
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 38 (01) : 65 - 66
  • [40] A new formulation for orally disintegrating tablets using a suspension spray-coating method
    Okuda, Y.
    Irisawa, Y.
    Okimoto, K.
    Osawa, T.
    Yamashita, S.
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2009, 382 (1-2) : 80 - 87